Ipsen to withdraw cancer drug acquired in buyout due to safety concerns
Source: BioPharma Dive - Latest News
Ipsen found cases of secondary malignancies in a confirmatory study of Tavzerik, a medicine it got in a purchase of Epizyme and that it has struggled to sell.